These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

490 related articles for article (PubMed ID: 30254079)

  • 1. FDA Approval: Blinatumomab for Patients with B-cell Precursor Acute Lymphoblastic Leukemia in Morphologic Remission with Minimal Residual Disease.
    Jen EY; Xu Q; Schetter A; Przepiorka D; Shen YL; Roscoe D; Sridhara R; Deisseroth A; Philip R; Farrell AT; Pazdur R
    Clin Cancer Res; 2019 Jan; 25(2):473-477. PubMed ID: 30254079
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A closer look at blinatumomab.
    Mattison RJ
    Clin Adv Hematol Oncol; 2018 Jun; 16(6):412-414. PubMed ID: 30067611
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and efficacy of blinatumomab: a real world data.
    Apel A; Ofran Y; Wolach O; Shimony S; Ram R; Levi I; Zektser M; Koren-Michowitz M
    Ann Hematol; 2020 Apr; 99(4):835-838. PubMed ID: 32076826
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study.
    Topp MS; Gökbuget N; Stein AS; Zugmaier G; O'Brien S; Bargou RC; Dombret H; Fielding AK; Heffner L; Larson RA; Neumann S; Foà R; Litzow M; Ribera JM; Rambaldi A; Schiller G; Brüggemann M; Horst HA; Holland C; Jia C; Maniar T; Huber B; Nagorsen D; Forman SJ; Kantarjian HM
    Lancet Oncol; 2015 Jan; 16(1):57-66. PubMed ID: 25524800
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of bispecific T-cell engager blinatumomab and the potential to improve leukemia-free survival in B-cell acute lymphoblastic leukemia.
    Ribera JM
    Expert Rev Hematol; 2017 Dec; 10(12):1057-1067. PubMed ID: 29082835
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase II trial of the anti-CD19 bispecific T cell-engager blinatumomab shows hematologic and molecular remissions in patients with relapsed or refractory B-precursor acute lymphoblastic leukemia.
    Topp MS; Gökbuget N; Zugmaier G; Klappers P; Stelljes M; Neumann S; Viardot A; Marks R; Diedrich H; Faul C; Reichle A; Horst HA; Brüggemann M; Wessiepe D; Holland C; Alekar S; Mergen N; Einsele H; Hoelzer D; Bargou RC
    J Clin Oncol; 2014 Dec; 32(36):4134-40. PubMed ID: 25385737
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Blinatumomab for minimal residual disease in adults with B-cell precursor acute lymphoblastic leukemia.
    Gökbuget N; Dombret H; Bonifacio M; Reichle A; Graux C; Faul C; Diedrich H; Topp MS; Brüggemann M; Horst HA; Havelange V; Stieglmaier J; Wessels H; Haddad V; Benjamin JE; Zugmaier G; Nagorsen D; Bargou RC
    Blood; 2018 Apr; 131(14):1522-1531. PubMed ID: 29358182
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Blinatumomab in pediatric patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia.
    Queudeville M; Schlegel P; Heinz AT; Lenz T; Döring M; Holzer U; Hartmann U; Kreyenberg H; von Stackelberg A; Schrappe M; Zugmaier G; Feuchtinger T; Lang P; Handgretinger R; Ebinger M
    Eur J Haematol; 2021 Apr; 106(4):473-483. PubMed ID: 33320384
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Molecular response with blinatumomab in relapsed/refractory B-cell precursor acute lymphoblastic leukemia.
    Gökbuget N; Kantarjian HM; Brüggemann M; Stein AS; Bargou RC; Dombret H; Fielding AK; Heffner L; Rigal-Huguet F; Litzow M; O'Brien S; Zugmaier G; Gao S; Nagorsen D; Forman SJ; Topp MS
    Blood Adv; 2019 Oct; 3(20):3033-3037. PubMed ID: 31648325
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term survival and T-cell kinetics in relapsed/refractory ALL patients who achieved MRD response after blinatumomab treatment.
    Zugmaier G; Gökbuget N; Klinger M; Viardot A; Stelljes M; Neumann S; Horst HA; Marks R; Faul C; Diedrich H; Reichle A; Brüggemann M; Holland C; Schmidt M; Einsele H; Bargou RC; Topp MS
    Blood; 2015 Dec; 126(24):2578-84. PubMed ID: 26480933
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Survival after blinatumomab treatment in pediatric patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia.
    Gore L; Locatelli F; Zugmaier G; Handgretinger R; O'Brien MM; Bader P; Bhojwani D; Schlegel PG; Tuglus CA; von Stackelberg A
    Blood Cancer J; 2018 Aug; 8(9):80. PubMed ID: 30190453
    [No Abstract]   [Full Text] [Related]  

  • 12. Blinatumomab for Acute Lymphoblastic Leukemia: The First Bispecific T-Cell Engager Antibody to Be Approved by the EMA for Minimal Residual Disease.
    Ali S; Moreau A; Melchiorri D; Camarero J; Josephson F; Olimpier O; Bergh J; Karres D; Tzogani K; Gisselbrecht C; Pignatti F
    Oncologist; 2020 Apr; 25(4):e709-e715. PubMed ID: 32297447
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pediatric posttransplant relapsed/refractory B-precursor acute lymphoblastic leukemia shows durable remission by therapy with the T-cell engaging bispecific antibody blinatumomab.
    Schlegel P; Lang P; Zugmaier G; Ebinger M; Kreyenberg H; Witte KE; Feucht J; Pfeiffer M; Teltschik HM; Kyzirakos C; Feuchtinger T; Handgretinger R
    Haematologica; 2014 Jul; 99(7):1212-9. PubMed ID: 24727818
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Blinatumomab for MRD-Negative Acute Lymphoblastic Leukemia in Adults.
    Litzow MR; Sun Z; Mattison RJ; Paietta EM; Roberts KG; Zhang Y; Racevskis J; Lazarus HM; Rowe JM; Arber DA; Wieduwilt MJ; Liedtke M; Bergeron J; Wood BL; Zhao Y; Wu G; Chang TC; Zhang W; Pratz KW; Dinner SN; Frey N; Gore SD; Bhatnagar B; Atallah EL; Uy GL; Jeyakumar D; Lin TL; Willman CL; DeAngelo DJ; Patel SB; Elliott MA; Advani AS; Tzachanis D; Vachhani P; Bhave RR; Sharon E; Little RF; Erba HP; Stone RM; Luger SM; Mullighan CG; Tallman MS
    N Engl J Med; 2024 Jul; 391(4):320-333. PubMed ID: 39047240
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia.
    Kantarjian H; Stein A; Gökbuget N; Fielding AK; Schuh AC; Ribera JM; Wei A; Dombret H; Foà R; Bassan R; Arslan Ö; Sanz MA; Bergeron J; Demirkan F; Lech-Maranda E; Rambaldi A; Thomas X; Horst HA; Brüggemann M; Klapper W; Wood BL; Fleishman A; Nagorsen D; Holland C; Zimmerman Z; Topp MS
    N Engl J Med; 2017 Mar; 376(9):836-847. PubMed ID: 28249141
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Blinatumomab as first salvage versus second or later salvage in adults with relapsed/refractory B-cell precursor acute lymphoblastic leukemia: Results of a pooled analysis.
    Topp MS; Stein AS; Gökbuget N; Horst HA; Boissel N; Martinelli G; Kantarjian H; Brüggemann M; Chen Y; Zugmaier G
    Cancer Med; 2021 Apr; 10(8):2601-2610. PubMed ID: 33734596
    [TBL] [Abstract][Full Text] [Related]  

  • 17. FDA Supplemental Approval: Blinatumomab for Treatment of Relapsed and Refractory Precursor B-Cell Acute Lymphoblastic Leukemia.
    Pulte ED; Vallejo J; Przepiorka D; Nie L; Farrell AT; Goldberg KB; McKee AE; Pazdur R
    Oncologist; 2018 Nov; 23(11):1366-1371. PubMed ID: 30018129
    [TBL] [Abstract][Full Text] [Related]  

  • 18. FDA Approval: Blinatumomab.
    Przepiorka D; Ko CW; Deisseroth A; Yancey CL; Candau-Chacon R; Chiu HJ; Gehrke BJ; Gomez-Broughton C; Kane RC; Kirshner S; Mehrotra N; Ricks TK; Schmiel D; Song P; Zhao P; Zhou Q; Farrell AT; Pazdur R
    Clin Cancer Res; 2015 Sep; 21(18):4035-9. PubMed ID: 26374073
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of minimal residual disease response and of status of disease on survival after blinatumomab in B-cell acute lymphoblastic leukemia: results from a real-life study.
    Leotta S; Markovic U; Duminuco A; Mulè A; Porretto F; Federico V; Gentile M; Pastore D; Nigro LL; Selleri C; Serio B; Calafiore V; Patti C; Mauro E; Vetro C; Maugeri C; Parisi M; Fiumara P; Parrinello L; Marino S; Scuderi G; Garibaldi B; Musso M; Renzo ND; Vigna E; Martino EA; Raimondo FD; Milone G
    Ann Hematol; 2024 Sep; 103(9):3701-3712. PubMed ID: 38609726
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeted therapy with the T-cell-engaging antibody blinatumomab of chemotherapy-refractory minimal residual disease in B-lineage acute lymphoblastic leukemia patients results in high response rate and prolonged leukemia-free survival.
    Topp MS; Kufer P; Gökbuget N; Goebeler M; Klinger M; Neumann S; Horst HA; Raff T; Viardot A; Schmid M; Stelljes M; Schaich M; Degenhard E; Köhne-Volland R; Brüggemann M; Ottmann O; Pfeifer H; Burmeister T; Nagorsen D; Schmidt M; Lutterbuese R; Reinhardt C; Baeuerle PA; Kneba M; Einsele H; Riethmüller G; Hoelzer D; Zugmaier G; Bargou RC
    J Clin Oncol; 2011 Jun; 29(18):2493-8. PubMed ID: 21576633
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.